Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joe Marion

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Healthcare Informatics : the Business Magazine for Information and Communication Systems|February 23, 2012
Cardiovascular information systemsJoe Marion
Statistics in Medicine|May 14, 2022
Bayesian model of disease progression in mucopolysaccaridosis IIIAJoe Marion, Juan Ruiz, Benjamin R Saville
Pharmaceutical Statistics|April 27, 2024
Optimal sample size division in two-stage seamless designsLindsay R Berry, Joe Marion, Scott M Berry, et al.
Drugs|October 26, 2022
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Maha Assi, Christine Lee, et al.
Drugs|November 7, 2022
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Maha Assi, Christine Lee, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
JAMA|December 10, 2024
High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial, Israel S Maia, Letícia Kawano-Dourado, et al.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Healthcare Informatics : the Business Magazine for Information and Communication Systems|February 23, 2012
Cardiovascular information systemsJoe Marion
Statistics in Medicine|May 14, 2022
Bayesian model of disease progression in mucopolysaccaridosis IIIAJoe Marion, Juan Ruiz, Benjamin R Saville
Pharmaceutical Statistics|April 27, 2024
Optimal sample size division in two-stage seamless designsLindsay R Berry, Joe Marion, Scott M Berry, et al.
Drugs|October 26, 2022
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Maha Assi, Christine Lee, et al.
Drugs|November 7, 2022
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Maha Assi, Christine Lee, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
JAMA|December 10, 2024
High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial, Israel S Maia, Letícia Kawano-Dourado, et al.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Pageof 1